Optimization of the complex therapy of chronic pancreatitis with metabolic syndrome
Babinets, L.S.; Melnyk, N.A.; Shevchenko, N.O.; Sasyk, G.M.; Zemlyak, O.S.; Kopach, O.Y.; Fedoriv, O.Y.
Wiadomosci Lekarskie 71(2 Part 1): 337-340
2018
ISSN/ISBN: 0043-5147 PMID: 29729169 Document Number: 697156
Inroduction: The most common reasons of chronic pancreatitis are alcohol abuse, biliary tract and liver diseases, stomach and duodenum, hyperlipidemia, which is often associated with metabolic syndrome. The aim: to study the effectiveness of using medicine omega-3 polyunsaturated fatty acids in standard therapy to the correction of lipids and prooxidant-antioxidant disorders in patients with chronic pancreatitis and metabolic syndrome. Materials and methods: The study included 90 patients with chronic pancreatitis with metabolic syndrome. They were divided into two groups: I group (45 patients) received standard treatment; II group (45 patients) along with baseline therapy received medication omega-3 polyunsaturated fatty acids (Omacor) for 2 capsules (1680 mg) for one month. Results: After treatment the lipid blood spectrum and prooxidant-antioxidant status have improved. Conclusions: Adding to the complex therapy of patients with chronic pancreatitis and the metabolic syndrome of the medicine omega-3 polyunsaturated fatty acids helps to improve the lipid and prooxidation-antioxidant status more significantly compared with standard baseline therapy.